三种方法获取胸水细胞蜡块中肿瘤细胞进行EGFR基因检测
发布时间：2019-07-04 07:34
【摘要】：正随着分子生物学技术的广泛应用,肿瘤的分子检测与临床靶向用药为患者提供新的治疗。目前,肺癌已进入精准治疗时代,方案及药物的选择是根据其组织学亚型和分子学检测结果共同制定[1]。近年以表皮生长因子受体(epidermal growth factor receptor,EGFR)为靶点的分子靶向治疗已成为非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗方案,然而只有约1/3的患者存在EGFR敏感突变位点,对EG-
[Abstract]:With the wide application of molecular biology technology, tumor molecular detection and clinical targeting drugs provide new treatment for patients. At present, lung cancer has entered the era of accurate treatment, and the choice of schemes and drugs is based on the results of histologic subtypes and molecular tests [1]. In recent years, molecular targeted therapy targeting epidermis growth factor receptor (epidermal growth factor receptor,EGFR has become a treatment for non-small cell lung cancer (non-small cell lung cancer,NSCLC). However, only about 1 鈮，
本文编号：2509743
[Abstract]:With the wide application of molecular biology technology, tumor molecular detection and clinical targeting drugs provide new treatment for patients. At present, lung cancer has entered the era of accurate treatment, and the choice of schemes and drugs is based on the results of histologic subtypes and molecular tests [1]. In recent years, molecular targeted therapy targeting epidermis growth factor receptor (epidermal growth factor receptor,EGFR has become a treatment for non-small cell lung cancer (non-small cell lung cancer,NSCLC). However, only about 1 鈮，
本文编号：2509743
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2509743.html
